Compare JJSF & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | OGN |
|---|---|---|
| Founded | 1971 | 1923 |
| Country | United States | United States |
| Employees | 1800 | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1995 | 2020 |
| Metric | JJSF | OGN |
|---|---|---|
| Price | $89.88 | $13.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $140.00 | $11.40 |
| AVG Volume (30 Days) | 230.3K | ★ 2.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.67% | 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.99 | 0.95 |
| Revenue | $1,022,038,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $0.30 | $0.45 |
| Revenue Next Year | $1.70 | $1.67 |
| P/E Ratio | $45.16 | ★ $14.47 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $68.87 | $5.69 |
| 52 Week High | $114.06 | $13.76 |
| Indicator | JJSF | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.33 | 72.40 |
| Support Level | $88.35 | $13.46 |
| Resistance Level | $95.69 | N/A |
| Average True Range (ATR) | 2.50 | 0.04 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 55.29 | 93.18 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.